CREATING A FUTURE WORTH LIVING. FOR PATIENTS. WORLDWIDE. EVERY DAY.

WHO WE ARE

Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 3.8 million patients worldwide regularly undergo dialysis treatment. We care for more than 345,000 dialysis patients around the world. Their well-being always comes first. Since Fresenius Medical Care was founded in 1996, our aim has been to improve our patients’ quality of life by offering them high-quality products as well as innovative technologies and therapies.

WHAT WE DO

With around 123,000 employees today, we intend to grow further and continue to use our experience, innovative research and value-based care approach to provide the best possible care for our patients. 2021 and the COVID-19 pandemic reminded us once again of the vulnerable patient population we serve and also showed the commitment of our employees to our patients.
We are at our best when we work as one company with our shared purpose to create a future worth living for our patients, worldwide, every day. Together, we can demonstrate what health care can accomplish.”

RICE POWELL
CEO AND CHAIRMAN OF THE MANAGEMENT BOARD
KIDNEY FAILURE

CHRONIC KIDNEY FAILURE is the permanent failure of the kidney resulting from a slow and progressive loss of renal function over several years. Patients with chronic kidney failure have to regularly undergo dialysis treatment, either in a dialysis center or at home.

ACUTE KIDNEY FAILURE is the acute loss of renal function. Patients with acute kidney failure are treated in an intensive care unit over the course of several days, usually 24 hours a day. After a while, the kidneys generally regain their function to such an extent that acute dialysis is no longer required.

DIALYSIS is a life-saving blood cleansing procedure that substitutes the function of the kidney in case of renal failure.

CAUSES

- Diabetes
- High blood pressure
- Various forms of infections

AROUND 3.8 MILLION PEOPLE WORLDWIDE DEPEND ON DIALYSIS TREATMENT

DIALYSIS METHODS FOR TREATING CHRONIC KIDNEY FAILURE

1. IN-CENTER DIALYSIS
   A treatment method in which the patient’s blood flows through plastic bloodlines into a special filter, the dialyzer. In the dialyzer, waste products from metabolic processes and excess water are removed from the blood and transported away in the dialysate. Afterwards, the purified blood is returned to the patient’s body.

2. HOME HEMODIALYSIS
   For some dialysis patients, this treatment method presents a viable alternative to in-center dialysis. Studies have shown that patients perceive significant benefits when dialyzing at home.

3. PERITONEAL DIALYSIS
   A treatment method that uses the patient’s peritoneum, i.e., the lining covering the inner wall of the abdominal cavity and the abdominal organs, as the dialyzing membrane.

85% OF DIALYSIS TREATMENTS IN THE U.S. PERFORMED IN-CENTER

15% OF DIALYSIS TREATMENTS PERFORMED AT HOME

3.8 MILLION PEOPLE WORLDWIDE DEPEND ON DIALYSIS TREATMENT

CHRONIC KIDNEY FAILURE:

- Around 3.8 million people worldwide depend on dialysis treatment.
- Causes include diabetes, high blood pressure, and various forms of infections.

ACUTE KIDNEY FAILURE:

- Is the acute loss of renal function.
- Patients treated in an intensive care unit for several days, usually 24 hours a day.
- Kidneys generally regain function, so dialysis may not be required.

DIALYSIS:

- Life-saving procedure substituting kidney function.
- Treatment options include in-center and home hemodialysis, as well as peritoneal dialysis.

IN-CENTER DIALYSIS:

- Treatment method involving plastic bloodlines and a dialyzer.
- Waste products and excess water removed from the blood.
- Purified blood returned to the patient.

HOME HEMODIALYSIS:

- Viable alternative to in-center dialysis.
- Studies show significant benefits for patients.

PERITONEAL DIALYSIS:

- Uses the patient’s peritoneum as a dialyzing membrane.
- Treats waste products and excess water.
- Purified blood returned to the patient.
OUR PORTFOLIO

HEALTH CARE SERVICES
- End-Stage Renal Disease-related treatments
- End-Stage Renal Disease-related laboratory testing services
- Acute dialysis services
- Value and risk-based care programs
- Pharmacy services
- Vascular, cardiovascular and endovascular specialty services as well as ambulatory surgery center services
- Physician nephrology and cardiology services
- Ambulant treatment services

MORE THAN

1,611

MILLION DIALYZERS PRODUCED IN 2021

4,171

DIALYSIS CENTERS IN AROUND 50 COUNTRIES

WE ARE THE CLEAR MARKET LEADER IN THE PRODUCTION OF HEMODIALYSIS MACHINES

HEALTH CARE PRODUCTS
- Hemodialysis machines and peritoneal dialysis cyclers
- Dialyzers
- Peritoneal dialysis solutions
- Hemodialysis concentrates, solutions, and granulates
- Bloodlines
- Renal pharmaceuticals
- Systems for water treatment
- Other equipment and medical devices
- Acute cardiopulmonary products
- Apheresis products

MORE THAN

2,022

IMPROVEMENTS MADE TO OUR DIALYSIS MACHINES, DIALYZERS, AND SOLUTION PRODUCTS

AROUND

53

MILLION DIALYSIS TREATMENTS IN 2021
**SELECTED KEY FIGURES**
in € BN, except where otherwise specified

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating income</td>
<td>1.85</td>
<td>2.30</td>
<td>(17 %) cc</td>
</tr>
<tr>
<td>Operating income excl. special items 2</td>
<td>1.92</td>
<td>2.50</td>
<td>(21 %) cc</td>
</tr>
<tr>
<td>Basic earnings per share in €</td>
<td>3.31</td>
<td>3.96</td>
<td>(14 %) cc</td>
</tr>
<tr>
<td>Basic earnings per share excl. special items 2 in €</td>
<td>3.48</td>
<td>4.62</td>
<td>(23 %) cc</td>
</tr>
<tr>
<td>Net cash provided by (used in) operating activities</td>
<td>2.49</td>
<td>4.23</td>
<td>70 %</td>
</tr>
<tr>
<td>Free cash flow 3</td>
<td>1.66</td>
<td>3.20</td>
<td>(48 %)</td>
</tr>
<tr>
<td>Capital expenditures, net</td>
<td>(0.83)</td>
<td>(1.04)</td>
<td>(25 %)</td>
</tr>
<tr>
<td>Acquisitions and investments excl. investments in debt securities</td>
<td>(0.43)</td>
<td>(0.26)</td>
<td>68 %</td>
</tr>
<tr>
<td>Operating income margin excl. special items 2 in %</td>
<td>10.9</td>
<td>14.0</td>
<td>6 %</td>
</tr>
<tr>
<td>Return on invested capital (ROIC) 4 in %</td>
<td>4.9</td>
<td>5.8</td>
<td></td>
</tr>
<tr>
<td>Net leverage ratio 5</td>
<td>3.3</td>
<td>2.7</td>
<td></td>
</tr>
<tr>
<td>Equity ratio (equity/total assets) 5 in %</td>
<td>40.7</td>
<td>38.9</td>
<td></td>
</tr>
</tbody>
</table>

cc = at constant currency

---

1 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
2 2021: costs related to the FME25 program; 2020: impairment of goodwill and trade names in the Latin America segment
3 Net cash provided by (used in) operating activities after capital expenditures, before acquisitions, investments, and dividends
4 See calculation in form 20-F 2021, chapter “operating and financial review and prospects”, section “financial position”
5 As of December 31 of the respective year
OUR REGIONS

Average annual growth rate of dialysis patients (2022-2025) based on company data, estimates, and assumptions regarding further development of the global COVID-19 pandemic

Company headquarters and regional headquarters
Regional headquarters

NORTH AMERICA 2021

Revenue
Health care services
Health care products
Employees
Patients
Treatments
Dialysis centers
€12.1 BN
€11.0 BN
€1.1 BN
60,782
209,291
32 M
2,695

LATIN AMERICA 2021

Revenue
Health care services
Health care products
Employees
Patients
Treatments
Dialysis centers
€0.7 BN
€0.5 BN
€0.2 BN
11,652
36,775
6 M
250

EUROPE, MIDDLE EAST AND AFRICA 2021

Revenue
Health care services
Health care products
Employees
Patients
Treatments
Dialysis centers
€2.8 BN
€1.4 BN
€1.4 BN
20,156
65,599
10 M
821

ASIA-PACIFIC 2021

Revenue
Health care services
Health care products
Employees
Patients
Treatments
Dialysis centers
€2.0 BN
€1.0 BN
€1.0 BN
11,766
33,760
5 M
405

1 Full-time equivalents
### Dividend per Share in €

<table>
<thead>
<tr>
<th>Year</th>
<th>Dividend per Share in €</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>1.06</td>
</tr>
<tr>
<td>2018</td>
<td>1.17</td>
</tr>
<tr>
<td>2019</td>
<td>1.20</td>
</tr>
<tr>
<td>2020</td>
<td>1.34</td>
</tr>
<tr>
<td>2021</td>
<td><strong>1.35</strong>&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>1 Planned proposal to be approved by the Annual General Meeting on May 12, 2022</sup>

### Share Price Performance 2021

**Share Price in €**

<table>
<thead>
<tr>
<th>Month</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan.</td>
<td>55.78</td>
</tr>
<tr>
<td>Feb.</td>
<td>55.78</td>
</tr>
<tr>
<td>March</td>
<td>55.78</td>
</tr>
<tr>
<td>April</td>
<td>55.78</td>
</tr>
<tr>
<td>May</td>
<td>55.78</td>
</tr>
<tr>
<td>June</td>
<td>55.78</td>
</tr>
<tr>
<td>July</td>
<td>55.78</td>
</tr>
<tr>
<td>Aug.</td>
<td>55.78</td>
</tr>
<tr>
<td>Sept.</td>
<td>55.78</td>
</tr>
<tr>
<td>Oct.</td>
<td>55.78</td>
</tr>
<tr>
<td>Nov.</td>
<td>55.78</td>
</tr>
<tr>
<td>Dec.</td>
<td>55.78</td>
</tr>
</tbody>
</table>

**Year High:** 72.96

**Year Low:** 55.78

__Source: Bloomberg data__

### Basic Share Data

**Ticker Symbols**

<table>
<thead>
<tr>
<th>Exchange</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frankfurt Stock Exchange/Prime Standard</td>
<td>FME</td>
</tr>
<tr>
<td>New York Stock Exchange (NYSE)</td>
<td>FMS</td>
</tr>
<tr>
<td>Reuters: XETRA/ADR NYSE</td>
<td>FMEG.DE/FMS.N</td>
</tr>
<tr>
<td>Bloomberg: XETRA/ADR NYSE</td>
<td>FME GY/FMS US</td>
</tr>
</tbody>
</table>

**Security Identification Codes**

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>WKN</td>
<td>578580</td>
</tr>
<tr>
<td>ISIN</td>
<td>DE0005785802</td>
</tr>
<tr>
<td>CUSIP (NYSE)</td>
<td>358029106</td>
</tr>
</tbody>
</table>

### Financial Calendar 2022

- **May 4:** Report on first quarter
- **August 2:** Report on second quarter
- **November 1:** Report on third quarter

**Key Dates:**

- **May 12:** Annual General Meeting
- **May 17:** Payment of dividend

__Subject to change__

### Basic Financial Notes

- **Share Price Performance:**
  - **Basis:** Share price in €
  - **High:** 72.96
  - **Low:** 55.78

**Profile:**

- **Ticker Symbols:**
  - Frankfurt Stock Exchange/Prime Standard: FME
  - New York Stock Exchange (NYSE): FMS
  - Reuters: XETRA/ADR NYSE: FMEG.DE/FMS.N
  - Bloomberg: XETRA/ADR NYSE: FME GY/FMS US

**Security Identification Codes:**

- **WKN:** 578580
- **ISIN:** DE0005785802
- **CUSIP (NYSE):** 358029106

**Payment of Dividend:**

- Subject to the approval by the Annual General Meeting

### Profile Profile

- **Share Price Performance:**
  - **Basis:** Share price in €
  - **High:** 72.96
  - **Low:** 55.78

**Profile:**

- **Ticker Symbols:**
  - Frankfurt Stock Exchange/Prime Standard: FME
  - New York Stock Exchange (NYSE): FMS
  - Reuters: XETRA/ADR NYSE: FMEG.DE/FMS.N
  - Bloomberg: XETRA/ADR NYSE: FME GY/FMS US

**Security Identification Codes:**

- **WKN:** 578580
- **ISIN:** DE0005785802
- **CUSIP (NYSE):** 358029106

**Payment of Dividend:**

- Subject to the approval by the Annual General Meeting